{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:09:12Z","timestamp":1770062952450,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"The Scientific and Technological Research Council of Turkey","award":["315S296"],"award-info":[{"award-number":["315S296"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.expneurol.2019.02.015","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T16:45:21Z","timestamp":1551285921000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats"],"prefix":"10.1016","volume":"317","author":[{"given":"Mehmet","family":"B\u00fclb\u00fcl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Sinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutay Ayd\u0131n","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysel","family":"A\u011far","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2019.02.015_bb0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1468-1331.2009.02900.x","article-title":"Neurotransmission in Parkinson's disease: beyond dopamine","volume":"17","author":"Barone","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00210-009-0480-2","article-title":"Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice","volume":"381","author":"Boeck","year":"2010","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","article-title":"Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems","volume":"36","author":"Brichta","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0025","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/npp.2009.37","article-title":"Persistent increase of alcohol-seeking evoked by neuropeptide S: an effect mediated by the hypothalamic hypocretin system","volume":"34","author":"Cannella","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2011.02.009","article-title":"Intraventricular administration of neuropeptide S has reward-like effects","volume":"658","author":"Cao","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0035","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.peptides.2009.07.004","article-title":"Lithium attenuates behavioral and biochemical effects of neuropeptide S in mice","volume":"30","author":"Castro","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0040","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pbb.2008.10.015","article-title":"Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam","volume":"91","author":"Castro","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cne.22606","article-title":"Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry","volume":"519","author":"Clark","year":"2011","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0055","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","article-title":"Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease","volume":"52","author":"Dexter","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbr.2014.03.002","article-title":"Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice","volume":"266","author":"Didonet","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120272","article-title":"Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a \"normal\"-anxiety one","volume":"10","author":"Dine","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.npep.2017.04.005","article-title":"Neuropeptide S increases motor activity and thermogenesis in the rat through sympathetic activation","volume":"65","author":"Ensho","year":"2017","journal-title":"Neuropeptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0075","doi-asserted-by":"crossref","first-page":"a008862","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson's disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold. Spring Harb. Perspect. Med."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5603\/FHC.2012.0032","article-title":"Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease","volume":"50","author":"Hacioglu","year":"2012","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.neuroscience.2010.10.020","article-title":"Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system","volume":"172","author":"Leonard","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00213-008-1080-4","article-title":"Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders","volume":"197","author":"Leonard","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.peptides.2015.07.024","article-title":"Neuropeptide S increases locomotion activity through corticotropin-releasing factor receptor 1 in substantia nigra of mice","volume":"71","author":"Li","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0100","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0105","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1523\/JNEUROSCI.0299-07.2007","article-title":"Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease","volume":"27","author":"Lopez","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neuropharm.2011.08.016","article-title":"Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects","volume":"62","author":"Lukas","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-8069-10-32","article-title":"Nasal application of neuropeptide S inhibits arthritis pain-related behaviors through an action in the amygdala","volume":"10","author":"Medina","year":"2014","journal-title":"Mol. Pain"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.peptides.2010.02.006","article-title":"Microinjection of neuropeptide S into the rat ventral tegmental area induces hyperactivity and increases extracellular levels of dopamine metabolites in the nucleus accumbens shell","volume":"31","author":"Mochizuki","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jneumeth.2006.06.001","article-title":"Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model","volume":"158","author":"Monville","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/10253890701248673","article-title":"Neuropeptide S: a novel modulator of stress and arousal","volume":"10","author":"Okamura","year":"2007","journal-title":"Stress"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0135","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1124\/jpet.107.135103","article-title":"Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor","volume":"325","author":"Okamura","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuropharm.2009.06.027","article-title":"Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801","volume":"58","author":"Okamura","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0145","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/npp.2010.207","article-title":"Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain","volume":"36","author":"Okamura","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0150","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.06.028","article-title":"Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice","volume":"99","author":"Pacheco","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0155","doi-asserted-by":"crossref","first-page":"25234","DOI":"10.1074\/jbc.M401229200","article-title":"Lithium-calcium exchange is mediated by a distinct potassium-independent sodium-calcium exchanger","volume":"279","author":"Palty","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0160","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1523\/JNEUROSCI.5256-08.2009","article-title":"Neuropeptide S reinstates cocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice","volume":"29","author":"Paneda","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0165","first-page":"27","article-title":"Neuronal nitric oxide synthase phosphorylation induced by docosahexaenoic acid protects dopaminergic neurons in an experimental model of Parkinson's disease","volume":"56","author":"Parlak","year":"2018","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0170","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1997"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pbb.2012.09.001","article-title":"Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice","volume":"103","author":"Ramos","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/bjp.2008.96","article-title":"Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice","volume":"154","author":"Rizzi","year":"2008","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0185","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2017.06.025","article-title":"Neuropeptide S (NPS) is a neuropeptide with cellular actions in arousal and anxiety-related nuclei: functional implications for effects of NPS on wakefulness and mood","volume":"126","author":"Roncace","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0190","doi-asserted-by":"crossref","first-page":"20809","DOI":"10.1074\/jbc.M601846200","article-title":"Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation","volume":"281","author":"Roth","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0195","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0270(98)00078-8","article-title":"The overall rod performance test in the MPTP-treated-mouse model of parkinsonism","volume":"83","author":"Rozas","year":"1998","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0200","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.peptides.2010.02.012","article-title":"Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68","volume":"31","author":"Ruzza","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.108","article-title":"In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative","volume":"3","author":"Ruzza","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.talanta.2013.03.082","article-title":"Quantitative determination of neurotransmitters, metabolites and derivates in microdialysates by UHPLC-tandem mass spectrometry","volume":"114","author":"Santos-Fandila","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0215","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-4159.2010.06947.x","article-title":"Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex","volume":"115","author":"Si","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2019.02.015_bb2000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00351-3","article-title":"Intracerebroventricular injection of apelin-13 reduces food intake in the rat","volume":"353","author":"Sunter","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0220","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.peptides.2008.08.014","article-title":"Anxiolytic-like effect of neuropeptide S in the rat defensive burying","volume":"29","author":"Vitale","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuron.2004.08.005","article-title":"Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects","volume":"43","author":"Xu","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2019.02.015_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cne.21159","article-title":"Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain","volume":"500","author":"Xu","year":"2007","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0235","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","article-title":"Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease","volume":"93","author":"Yoritaka","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0240","first-page":"383","article-title":"Essential fatty acids and the brain: possible health implications","volume":"18","author":"Youdim","year":"2000","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.expneurol.2019.02.015_bb0245","first-page":"137","article-title":"Oxidative stress indices in Parkinson's disease : biochemical determination","volume":"62","author":"Youdim","year":"2001","journal-title":"Methods Mol. Med."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618303406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618303406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:09:31Z","timestamp":1739819371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488618303406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":49,"alternative-id":["S0014488618303406"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.02.015","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}